[EN] INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS<br/>[FR] DERIVES D'INDANE UTILISES COMME AGONISTES DU RECEPTEUR MUSCARINIQUE
申请人:LILLY CO ELI
公开号:WO2005009941A1
公开(公告)日:2005-02-03
The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.
这项发明涉及到Formula I的化合物,这些化合物是M-1肌氨酸受体的激动剂。
Indane derivates as muscarinic receptor agonists
申请人:Allen Rebecca Jennifer
公开号:US20070060587A1
公开(公告)日:2007-03-15
The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.
本发明涉及I式化合物:I,它们是M-1肌动蛋白受体的激动剂。
INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS
申请人:ELI LILLY AND COMPANY
公开号:EP1644320B1
公开(公告)日:2008-01-16
US7265246B2
申请人:——
公开号:US7265246B2
公开(公告)日:2007-09-04
Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase
作者:Sanjeev Kumar、Daniel Jaller、Bhumika Patel、Judith M. LaLonde、James B. DuHadaway、William P. Malachowski、George C. Prendergast、Alexander J. Muller
DOI:10.1021/jm800512z
日期:2008.8.1
Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. With the goal of developing more potent IDO inhibitors, a systematic study of 4-phenylimidazole (4-PI) derivatives was undertaken. Computational docking experiments guided design and synthesis efforts with analogues of 4-PI. In particular, three interactions of 4-PI analogues with IDO were studied: the active site entrance, the interior of the active site, and the heme iron binding. The three most potent inhibitors (1, 17, and 18) appear to exploit interactions with C129 and S167 in the interior of the active site. All three inhibitors are approximately 10-fold more potent than 4-PI. The study represents the first example of enzyme inhibitor development with the recently reported crystal structure of IDO and offers important lessons in the search for more potent inhibitors.